Gyre Therapeutics(GYRE)
$4.21-0.31 (-6.86%)
GYRE
Gyre Therapeutics financials statements
$4.21
At close:-0.31 (-6.86%)
Want to see GYRE full AI Analyst Report?
Gyre Therapeutics (GYRE) Ratios
829 Followers
Gyre Therapeutics Ratios
GYRE's free cash flow for Q3 2026 was $-4.96M. For the 2026 fiscal year, GYRE's free cash flow was decreased by $-979.00K and operating cash flow was $-3.98M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.60 | 3.32 | 2.85 | 4.06 | 3.63 |
| Quick Ratio | 5.04 | 2.99 | 2.64 | 3.56 | 3.63 |
| Cash Ratio | 2.03 | 0.61 | 1.67 | 2.06 | 3.13 |
| Solvency Ratio | 0.31 | 0.51 | -0.90 | 0.27 | -6.01 |
| Operating Cash Flow Ratio | 0.06 | -0.19 | 1.29 | 0.87 | -5.91 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -42.36 |
| Net Current Asset Value | $ 78.52M | $ 37.78M | $ -45.37M | $ 37.12M | $ 36.90M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.04 |
| Debt-to-Equity Ratio | 0.01 | 0.03 | -0.03 | 0.01 | 0.06 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | -0.03 | 0.01 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.57 | 1.98 | -7.36 | 1.99 | 1.35 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -44.33 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.01 | 0.01 | 0.08 |
| Net Debt to EBITDA | -2.14 | -0.57 | -1.63 | -2.38 | 0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.35% | 96.33% | 95.91% | 95.31% | -4.52% |
| EBIT Margin | 12.38% | 15.35% | 16.94% | 9.00% | -1198.32% |
| EBITDA Margin | 14.51% | 16.85% | 17.92% | 10.10% | -1194.37% |
| Operating Profit Margin | 9.86% | 15.28% | -59.26% | 9.00% | -1140.99% |
| Pretax Profit Margin | 12.38% | 21.95% | -67.84% | 9.20% | -1198.32% |
| Net Profit Margin | 4.31% | 11.43% | -81.92% | 2.25% | -1198.32% |
| Continuous Operations Profit Margin | 8.47% | 16.92% | -75.35% | 4.22% | -1198.32% |
| Net Income Per EBT | 34.82% | 52.05% | 120.75% | 24.46% | 100.00% |
| EBT Per EBIT | 125.63% | 143.65% | 114.48% | 102.27% | 105.02% |
| Return on Assets (ROA) | 3.03% | 9.64% | -79.74% | 2.72% | -157.98% |
| Return on Equity (ROE) | 4.74% | 19.09% | 587.14% | 5.41% | -214.01% |
| Return on Capital Employed (ROCE) | 7.77% | 15.26% | -69.67% | 12.69% | -201.76% |
| Return on Invested Capital (ROIC) | 5.30% | 11.69% | -69.52% | 5.78% | -192.59% |
| Return on Tangible Assets | 3.11% | 9.77% | -80.92% | 2.78% | -157.98% |
| Earnings Yield | 0.80% | 1.17% | -5.93% | 0.38% | -21.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.16 | 3.63 | 6.74 | 6.55 | 4.04 |
| Payables Turnover | 43.68 | 35.96 | 13.06 | 39.29 | 1.19 |
| Inventory Turnover | 0.53 | 0.61 | 1.08 | 0.78 | 0.00 |
| Fixed Asset Turnover | 4.71 | 4.12 | 4.77 | 5.57 | 1.98 |
| Asset Turnover | 0.70 | 0.84 | 0.97 | 1.21 | 0.13 |
| Working Capital Turnover Ratio | 1.80 | 2.57 | 3.04 | 2.74 | 0.13 |
| Cash Conversion Cycle | 792.76 | 685.99 | 363.28 | 512.63 | -215.04 |
| Days of Sales Outstanding | 115.67 | 100.62 | 54.18 | 55.72 | 90.43 |
| Days of Inventory Outstanding | 685.45 | 595.52 | 337.05 | 466.21 | 0.00 |
| Days of Payables Outstanding | 8.36 | 10.15 | 27.95 | 9.29 | 305.47 |
| Operating Cycle | 801.12 | 696.14 | 391.23 | 521.92 | 90.43 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.01 | -0.04 | 0.39 | 0.14 | -2.73 |
| Free Cash Flow Per Share | -0.00 | -0.08 | 0.26 | 0.07 | -2.76 |
| Dividend Paid and CapEx Coverage Ratio | 0.85 | -1.16 | 0.11 | 0.01 | -99.83 |
| Capital Expenditure Coverage Ratio | 0.85 | -1.16 | 3.02 | 2.14 | -99.83 |
| Operating Cash Flow Coverage Ratio | 1.08 | -2.28 | 63.31 | 17.42 | -35.12 |
| Operating Cash Flow to Sales Ratio | 0.01 | -0.03 | 0.23 | 0.10 | -11.41 |
| Free Cash Flow Yield | -0.03% | -0.66% | 1.11% | 0.93% | -20.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 125.40 | 86.43 | -16.85 | 265.01 | -4.76 |
| Price-to-Sales (P/S) Ratio | 5.41 | 9.74 | 13.80 | 5.96 | 57.00 |
| Price-to-Book (P/B) Ratio | 5.95 | 16.26 | -98.95 | 14.35 | 10.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3504.29 | -152.11 | 90.50 | 107.42 | -4.94 |
| Price-to-Operating Cash Flow Ratio | 624.53 | -282.79 | 60.49 | 57.14 | -4.99 |
| Price-to-Earnings Growth (PEG) Ratio | -2.10 | -0.79 | 0.00 | -2.62 | 2.32 |
| Enterprise Value Multiple | 35.15 | 57.22 | 75.42 | 56.67 | -4.29 |
| Enterprise Value | 594.64M | 1.02B | 1.53B | 585.49M | 376.29M |
| EV to EBITDA | 35.15 | 57.22 | 75.42 | 56.67 | -4.29 |
| EV to Sales | 5.10 | 9.64 | 13.51 | 5.72 | 51.28 |
| EV to Free Cash Flow | -3303.57 | -150.60 | 88.58 | 103.10 | -4.45 |
| EV to Operating Cash Flow | 588.75 | -279.99 | 59.21 | 54.84 | -4.49 |
| Tangible Book Value Per Share | 1.54 | 1.14 | 0.19 | 0.92 | 1.34 |
| Shareholders’ Equity Per Share | 1.19 | 0.74 | -0.24 | 0.55 | 1.34 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.32 | 0.23 | -0.11 | 0.54 | 0.00 |
| Revenue Per Share | 1.30 | 1.24 | 1.72 | 1.33 | 0.24 |
| Net Income Per Share | 0.06 | 0.14 | -1.41 | 0.03 | -2.87 |
| Tax Burden | 0.35 | 0.52 | 1.21 | 0.24 | 1.00 |
| Interest Burden | 1.00 | 1.43 | -4.01 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.12 | 0.11 | 0.12 | 0.16 | 8.80 |
| SG&A to Revenue | 0.74 | 0.70 | 0.13 | 0.17 | 0.00 |
| Stock-Based Compensation to Revenue | 0.06 | 0.01 | 0.06 | 0.13 | 0.46 |
| Income Quality | 0.10 | -0.20 | -0.30 | 2.47 | 0.95 |
Currency in USD
